Featured Research

from universities, journals, and other organizations

Key to TB cure could lie underwater

Date:
March 7, 2013
Source:
University of Illinois at Chicago
Summary:
Researchers are collecting actinomycete bacteria from water throughout the world in a hunt for new antibiotics.

Brian Murphy, assistant professor of medicinal chemistry and pharmacognosy, collects bacteria from water throughout the world in a hunt for new antibiotics.
Credit: Image courtesy of University of Illinois at Chicago

The search for a cure for deadly infectious diseases has led Brian Murphy deep underwater.

Murphy, assistant professor of medicinal chemistry and pharmacognosy at the University of Illinois at Chicago, is collecting actinomycete bacteria from water throughout the world in a hunt for new antibiotics.

He and Scott Franzblau, director of UIC's Institute for Tuberculosis Research, are lead investigators on a new, three-year, $1.1 million grant from the Defense Department to find compounds to fight tuberculosis, a disease that killed more than 1.4 million people worldwide in 2011.

As a killer, tuberculosis -- caused by a bacterium that most often attacks the lungs -- is second only to HIV among infectious agents, according to the World Health Organization. The bacteria lie dormant in about one-third of the population, and 8 million new cases are reported annually.

U.S. military personnel face a much higher risk of tuberculosis than American civilians, due to their frequent deployment in developing countries where infection rates are higher, Murphy said. Some units are stationed in locations where the spread of tuberculosis is a major hazard.

"Novel drug scaffolds that can reduce the spread of tuberculosis throughout the military and quickly address a tuberculosis epidemic are in serious need," he said.

Murphy has so far collected a "library" of nearly 1,000 actinomycete strains, and 1,200 samples of biochemicals they produce, from marine waters off Massachusetts, Maine, the Florida Keys and Vietnam, and from the freshwater of the Great Lakes.

From his collection, he and Franzblau have identified eight aquatic actinomyces strains that target non-replicating tuberculosis. A promising new class of compounds with drug-like potency emerged from their screenings and is the focus of the new grant, Murphy said. It was isolated from sediment collected 260 feet below the surface of Lake Michigan.

"Freshwater environments are a new frontier for drug-lead discovery," Murphy said. "Actinomycetes have the ability to produce molecules that have a high potential for use as medicines, and very little is known about these bacteria in such environments."

The UIC team will be the first to explore each of the five Great Lakes for antibiotic-producing actinomycete bacteria and will evaluate the viability of freshwater systems as a source for drug-lead discovery.

"If we can understand the capacity for these bacteria to produce new, small-molecule drug leads, it will help guide a global freshwater discovery effort," Murphy said.

Multi-drug and extensively drug-resistant strains of tuberculosis, which are unaffected by first- and second-line drug regimens, are the most serious threat, Franzblau said.

"Perhaps the most problematic aspect of tuberculosis treatment is its duration," said Murphy. Franzblau said lengthy treatment is required to eliminate a persistent population of slow-growing or non-replicating tuberculosis.

UIC ranks among the nation's leading research universities and is Chicago's largest university with 27,500 students, 12,000 faculty and staff, 15 colleges and the state's major public medical center. A hallmark of the campus is the Great Cities Commitment, through which UIC faculty, students and staff engage with community, corporate, foundation and government partners in hundreds of programs to improve the quality of life in metropolitan areas around the world. For more information about UIC, please visit www.uic.edu.


Story Source:

The above story is based on materials provided by University of Illinois at Chicago. The original article was written by Sam Hostettler. Note: Materials may be edited for content and length.


Cite This Page:

University of Illinois at Chicago. "Key to TB cure could lie underwater." ScienceDaily. ScienceDaily, 7 March 2013. <www.sciencedaily.com/releases/2013/03/130307190524.htm>.
University of Illinois at Chicago. (2013, March 7). Key to TB cure could lie underwater. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/03/130307190524.htm
University of Illinois at Chicago. "Key to TB cure could lie underwater." ScienceDaily. www.sciencedaily.com/releases/2013/03/130307190524.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins